Pegaptanib
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.  Pegaptanib was granted FDA approval on 17 September 2004.